Splenectomy in myeloid metaplasia

Area of Science:

• Hematology
• Surgical Oncology

Background:

• Agnogenic myeloid metaplasia is a myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis.
• Splenomegaly is a common and often symptomatic manifestation of this condition, leading to complications like anemia, thrombocytopenia, and portal hypertension.

Purpose of the Study:

• To evaluate the efficacy and safety of splenectomy in managing symptomatic agnogenic myeloid metaplasia.
• To assess the impact of splenectomy on specific complications associated with the condition.

Main Methods:

• A retrospective analysis of 50 patients with agnogenic myeloid metaplasia who underwent splenectomy between 1960 and 1977.
• Categorization of patients based on presenting symptoms, including painful splenomegaly, refractory hemolytic anemia, refractory thrombocytopenia, and portal hypertension.

Main Results:

• Significant clinical benefit was observed in 25 of 26 patients with painful splenomegaly.
• Beneficial effects were also noted in patients with refractory hemolytic anemia (4/9), refractory thrombocytopenia (4/10), and portal hypertension (4/4).
• The overall postoperative mortality rate decreased significantly over time, with only one death in the last 21 patients, compared to four in the earlier series.

Conclusions:

• Splenectomy is an effective treatment for selected symptoms of agnogenic myeloid metaplasia, especially painful splenomegaly.
• Surgical outcomes and patient survival have improved with experience, suggesting a refined surgical approach.
• The procedure offers a survival benefit, averaging 25.5 months post-splenectomy.